Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 8/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648537 | 0.84 | AGXT (0.39) | IDO1 | |
| SCHEMBL1691492 | 0.83 | APP (0.52) | KMT2AALDH1A1 | |
| SCHEMBL791859 | 0.78 | IDO1 (0.63) | IDO1KMT2AMAOBTAAR1ALDH1A1 | |
| SCHEMBL8103605 | 0.78 | IDO1 (0.52) | IDO1KMT2AMAOBTAAR1ALDH1A1 | |
| SCHEMBL8935846 | 0.78 | PPARA (0.50) | IDO1KMT2AMAOB | |
| SCHEMBL19638101 | 0.78 | AGXT (0.41) | IDO1 | |
| SCHEMBL492736 | 0.78 | IDO1 (0.68) | IDO1KMT2AMAOBTAAR1ALDH1A1 | |
| SCHEMBL22821604 | 0.78 | RORC (0.38) | IDO1KMT2AMAOB | |
| SCHEMBL19240349 | 0.77 | IDO1 (0.64) | IDO1MAOBTAAR1 | |
| Boric Acid SCHEMBL28861430 | 0.77 | IDO1 (0.47) | IDO1KMT2AMAOBTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325937-B2 | Glycoside compound and preparation method therefor, composition, application, and intermediate | SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) | 2022-05-10 | — | — | US | disclosed |
| US-11208397-B2 | Small molecule antagonists of sumo related modification of CRMP2 and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210380595-A1 | 2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS | ARAXES PHARMA LLC (US) | 2021-12-09 | — | — | US | disclosed |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210115082-A1 | GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE | SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) | 2021-04-22 | — | — | US | disclosed |
| US-20210061773-A1 | COMPOUND AND USE THEREOF IN MEDICINE | CHANGSHA HOOZ BIOSCIENCE AND TECHNOLOGY CO., LTD (CN) | 2021-03-04 | — | — | US | disclosed |
| US-10774079-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2020-09-15 | — | — | US | disclosed |
| US-20200277271-A1 | SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2020-09-03 | — | — | US | disclosed |
| US-10421754-B2 | Quinazoline derivative | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2019-09-24 | — | — | US | disclosed |
| WO-2019141009-A1 | COMPOUND AND USE THEREOF IN MEDICINE | 长沙霍滋生物科技有限公司 | 2019-07-25 | — | — | WO | disclosed |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774079-B2 | Quinazoline derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | IDO1 2208/4885KMT2A 1659/4885MAOB 2680/4885 |
| US-10421754-B2 | Quinazoline derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | IDO1 2208/4885KMT2A 1659/4885MAOB 2680/4885 |
| US-20210380595-A1 | 2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS | KRAS, NRAS, G3BP2 | IDO1 4070/4885KMT2A 3129/4885MAOB 4541/4885 |
| US-11208397-B2 | Small molecule antagonists of sumo related modification of CRMP2 and uses thereof | SUMO2, SUMO1, SUMO3 | IDO1 3681/4885KMT2A 2071/4885MAOB 4667/4885 |
| US-20210061773-A1 | COMPOUND AND USE THEREOF IN MEDICINE | HDAC1, HDAC11, HDAC10 | IDO1 2429/4885KMT2A 173/4885MAOB 3769/4885 |
| US-11325937-B2 | Glycoside compound and preparation method therefor, composition, application, and intermediate | VEGFA, FLT4, FLT1 | IDO1 3327/4885KMT2A 4004/4885MAOB 1432/4885 |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | IDO1 2208/4885KMT2A 1659/4885MAOB 2680/4885 |
| US-20200277271-A1 | SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF | SUMO2, SUMO1, SUMO3 | IDO1 3681/4885KMT2A 2071/4885MAOB 4667/4885 |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | KRAS, NRAS, HRAS | IDO1 4758/4885KMT2A 2229/4885MAOB 4707/4885 |
| US-20210115082-A1 | GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE | VEGFA, FLT4, FLT1 | IDO1 3327/4885KMT2A 4004/4885MAOB 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.